A phase II/III trial to assess the safety, immunogenicity and preliminary efficacy of recombinant human EGF-rP64K/Montanide ISA 51 vaccine administered to patients with non-small-cell lung cancer (NSCLC) after receiving conventional first line chemotherapy
Phase of Trial: Phase II/III
Latest Information Update: 29 Sep 2011
At a glance
- Drugs BV NSCLC 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Sep 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Aug 2007 New trial record.